Novartis Venture Fund

Novartis Venture Fund

A corporate venture capital firm in Switzerland that focuses on companies that develop novel therapeutics and platforms

Novartis Venture Fund is a corporate venture capital firm in Switzerland that focuses on companies that develop novel therapeutics and platforms. Founded 1996 in Basel-Stadt, Switzerland by Argeris Karabelas, it invests in early stage ventures, late stage venture, post-IPO, secondary markets, seed, series A, series B, series C, and post-IPO equity. Its portfolio companies include TScan Therapeutics, GenSight Biologics, FORMA Therapeutics, Arctos Medical, and Enterprise Therapeutics. As of March 2020, Novartis Venture Fund has made 200 investments. Their most recent investment was on January 10, 2020, when TScan Therapeutics raised $35M. Novartis Venture Fund has had 51 exits, the most notable of which include PTC Therapeutics, Bicycle Therapeutics, and Akebia Therapeutics. The company has raised three funds, their latest being Novartis Option Fund (NOF). This fund was announced on January 1, 2009 and raised a total of $200M.

Timeline

2015

Founded

Funded Companies

Company
Description
Website
Industry
Location

A biopharmaceutical company focused on the research and development of antibiotics to treat serious infections

A company developing Hypoxia Inducible Factor therapies to treat kidney diseases and other conditions

Adicet Bio is a biotechnology company creating immune cell therapies for treating cancer and other diseases.

A provider of an online telemedicine service in California and focuses on creating a revolutionized patient experience and improving and optimizing clinical care through the advancements in machine learning and AI.

ImaginAb is an immune and oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient's health--enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.

Omeros is a Seattle-based biotechnology company founded by Konrad Tylka.

A company developing inhaled therapies to treat, prevent the spread of infectious and progressive respiratory diseases

A biopharmaceutical company developing stapled peptide therapeutics for the treatment of cancers and other diseases

A company developing diagnostic products to cure on-farm animal diseases

A pharmaceutical company developing products to address hemophilia

A company dedicated on the discovery and development of small molecule therapeutics to treat cancer

A biotechnology company developing medicines to treatment viral diseases

A biotechnology company developing treatments for sickle cell, cancer and other serious disease

A biopahramaceutical company developing protein-based therapeutics to treat inflammatory diseases and cancer

A company developing pepducin technology to produce therapeutics for regenerative medicine, diabetes, inflammation and cancer.

A oncology-based pharmaceutical company developing therapeutics for the protection of cancer patients from radiotherapy and chemotherapy side effects

A biotechnology company developing molecular reagent products and software for research and diagnostics

A biotechnology company focused in the development of molecular therapies to treat heart failure

Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells

A company that develops and commercializes therapies for prostate cancer and other hormonally-driven diseases

A biopharmaceutical company developing small molecule drugs for asthma, chronic allergy and inflammatory conditions

A biotechnology company that develops RNA interference therapeutics

A company that develops vaccines and monoclonal antibodies to treat gastrointestinal and respiratory conditions

57 Results
Page 1 of 3
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Bart Dzikowski

Head of Legal

David Morris

Venture Partner

Harry Kirsch

Chief Financial Officer

Lauren Silverman

Managing Director

Spyros Artavanis-Tsakonas

Chairman, Option Fund

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Twentyeight-Seven Therapeutics

Adicet Bio

Anaveon

Anokion

Athelas

Cala Health

Forendo Pharma

Renovacor

TScan Therapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.